Exelixis cut to Underperform at BofA on valuation and lack of catalysts
Source: SeekingAlpha
2026-01-05 13:26:16 ET
More on Exelixis
- Exelixis, Inc. (EXEL) Discusses Strategic Approach to Building Next-Generation Oncology Franchises at R&D Day - Slideshow
- Exelixis, Inc. (EXEL) Discusses Strategic Approach to Building Next-Generation Oncology Franchises at R&D Day Transcript
- Exelixis, Inc. (EXEL) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript
- LLY joins $1T club but doesn't feature in SA's top 10 large-cap healthcare stocks
- Exelixis narrows 2025 revenue guidance to $2.3B–$2.35B amid accelerated GI franchise expansion and new pivotal trials
Read the full article on Seeking Alpha
For further details see:
Exelixis cut to Underperform at BofA on valuation and lack of catalysts
Exelixis Inc.
NASDAQ: EXEL
EXEL Trading
0.07% G/L:
$40.86 Last:
740,799 Volume:
$41.665 Open:
EXEL Latest News
February 28, 2026 04:57:00 am
3 Reasons Exelixis Stock Could Deliver Market?Beating Returns Over the Next Decade
February 24, 2026 04:05:00 pm
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March
February 24, 2026 10:58:00 am
Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge
February 20, 2026 04:05:00 pm
Exelixis: The Cash?Generating Biotech That I Think Deserves a Closer Look in 2026
EXEL Stock Data
$11,614,618,641
260,551,394
1.54%
313
N/A
Biotechnology & Life Sciences
Healthcare
US
Alameda
